Crispr system based antiviral therapy
Номер патента: EP3648781A1
Опубликовано: 13-05-2020
Автор(ы): Cameron MYHRVOLD, Catherine Amanda FREIJE, Feng Zhang, Jonathan S. GOOTENBERG, Omar O. Abudayyeh, Pardis SABETI
Принадлежит: Broad Institute Inc, Harvard College, Massachusetts Institute of Technology
Опубликовано: 13-05-2020
Автор(ы): Cameron MYHRVOLD, Catherine Amanda FREIJE, Feng Zhang, Jonathan S. GOOTENBERG, Omar O. Abudayyeh, Pardis SABETI
Принадлежит: Broad Institute Inc, Harvard College, Massachusetts Institute of Technology
Реферат: The present invention offers a new approach for highly multiplexed, programmable antiviral therapies that directly target viral RNA, and can be flexibly adapted to target novel viruses or emerging outbreak pathogens. Class 2, type VI CRISPR system-based therapies can be used in combination with existing antiviral compounds for viruses where such compounds exist, either by increasing their efficacy or by preventing the evolution of specific drug resistance mutations. Perhaps most excitingly, if a virus evolves resistance to a specific guide RNA sequence, it is easy to switch to a different guide RNA sequence, or to design a new guide sequence to target the new mutation. Such approaches should prevent the widespread development of resistance to Class 2, type VI CRISPR system-based therapies.
Crispr system for genome editing
Номер патента: WO2020079574A9. Автор: Francesco Donati,Alessandra Renieri,Silvestro CONTICELLO,Francesca NICCHERI,Francesca MARI,Filomena Tiziana PAPA,Flaminia Clelia LORENZETTI. Владелец: Istituto Per Lo Studio, La Prevenzione E La Rete Oncologica (Ispro). Дата публикации: 2021-03-11.